395 related articles for article (PubMed ID: 21220502)
41. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
[TBL] [Abstract][Full Text] [Related]
42. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
[TBL] [Abstract][Full Text] [Related]
43. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
44. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
45. Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
Perez LE; Parquet N; Meads M; Anasetti C; Dalton W
Eur J Haematol; 2010 Mar; 84(3):212-22. PubMed ID: 19922463
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
Ivanov VN; Zhou H; Partridge MA; Hei TK
Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
[TBL] [Abstract][Full Text] [Related]
47. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Seol DW
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
[TBL] [Abstract][Full Text] [Related]
48. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
49. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
An J; Sun Y; Fisher M; Rettig MB
Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
[TBL] [Abstract][Full Text] [Related]
50. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
51. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5.
Kang YJ; Kim IY; Kim EH; Yoon MJ; Kim SU; Kwon TK; Choi KS
Exp Mol Med; 2011 Jan; 43(1):24-34. PubMed ID: 21150246
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Rieger J; Frank B; Weller M; Wick W
Cell Physiol Biochem; 2007; 20(1-4):23-34. PubMed ID: 17595512
[TBL] [Abstract][Full Text] [Related]
53. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
54. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
55. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
Koschny R; Holland H; Sykora J; Erdal H; Krupp W; Bauer M; Bockmuehl U; Ahnert P; Meixensberger J; Stremmel W; Walczak H; Ganten TM
J Neurooncol; 2010 Apr; 97(2):171-85. PubMed ID: 19768634
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
[TBL] [Abstract][Full Text] [Related]
57. Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-κB signalling inhibitor.
Omar HA; Arafa el-SA; Maghrabi IA; Weng JR
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):464-71. PubMed ID: 24401154
[TBL] [Abstract][Full Text] [Related]
58. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
59. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
[TBL] [Abstract][Full Text] [Related]
60. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Baritaki S; Yeung K; Palladino M; Berenson J; Bonavida B
Cancer Res; 2009 Nov; 69(21):8376-85. PubMed ID: 19843864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
